Theranostics: Nanoconstruct-based Theranostics

Their large surface area makes nanoconstructs nearly ideal as a platform for theranostic agents. When compared to small-molecule or biologics, nanoparticles can be synthesized with an excess of sites for conjugation. This allow for the development of multimodal agents that can serve as diagnostic, therapeutic, or both.


Ferumoxytol Theranostics

Heike Daldrup-Link, Radiology, Stanford University, Stanford, CA, USA

Nanoparticles for MR Imaging have been developing and ferumoxytol has been approved by the FDA as an iron supplement to treat anemia. Radiologists use it off label as a contrast agent for MR Imaging. This presentation will discuss how ferumoxytol distributes in the body, how we can use ferumoxytol to deliver therapeutics, and will touch on intrinsic therapeutic effects of ferumoxytol.


A novel theranostic strategy for MMP-14 expressing glioblastomas impacts survival

Suchismita Mohanty, Stanford University, Stanford, CA, USA

Talk Outline:

  • Challenges in Glioblastoma therapy
  • Theranostic nanoparticles: Concept and design
  • Matrix metalloproteinase-14 function
  • In vivo behavior of theranostic strategy


Ultrasound-triggered micro-to-nano conversion: Exploring porphyrin-bubble theranostic potential beyond the vasculature

Carly Pellow, University of Toronto, Toronto, Canada

Talk Outline:

  • Nanomedicine and the Tumor Microvasculature
  • Microbubbles and Ultrasound-Triggered Bio-effects
  • Porphyrin Microbubbles
  • In vivo protocols and outcomes

Home Widget 3

This is your third home widget box. To edit please go to Appearance > Widgets and choose 8th widget from the top in area 8 called Home Widget 3. Title is also manageable from widgets as well.